SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 120.01 |
| Enterprise Value ($M) | 165.58 |
| Book Value ($M) | -24.47 |
| Book Value / Share | -0.53 |
| Price / Book | -4.90 |
| NCAV ($M) | -43.10 |
| NCAV / Share | -0.94 |
| Price / NCAV | -2.78 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.14 |
| Return on Assets (ROA) | -0.05 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.88 |
| Current Ratio | 1.08 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 37.82 |
| Assets | 56.45 |
| Liabilities | 80.92 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 85.87 |
| Operating Income | 8.17 |
| Net Income | -8.31 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 2.38 |
| Cash from Investing | 0.94 |
| Cash from Financing | -21.49 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | Soleus Capital Master Fund, L.P. | 10.40 | -7.47 | |
| 13G/A | Hirschman Orin | 6.10 | -18.63 | |
| 13G/A | Nantahala Capital Management, LLC | 5.83 | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 22,611 | 376,346 | 6.01 | |
| 28,398 | 270,914 | 10.48 | |
| 34,453 | 248,613 | 13.86 | |
| 49,151 | 380,037 | 12.93 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| TENX – Tenax Therapeutics, Inc. | TGTX – TG Therapeutics, Inc. |
| THAR – Tharimmune, Inc. | TIL – Instil Bio, Inc. |
| TLSA – Tiziana Life Sciences Ltd |
Financial data and stock pages provided by
Fintel.io